Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Site search
Search
Menu
Search
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscription Services
Submission Forms
Promote Your Event
Place an Ad
Weather
News
Local News
Sports
Obituaries
Local Events
Photo Galleries
Video Gallery
e-Edition
Classifieds
Place an ad
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Arvinas Inc
(NQ:
ARVN
)
42.68
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 28, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
42.68
Bid (Size)
34.00 (1)
Ask (Size)
60.25 (1)
Prev. Close
42.68
Today's Range
42.68 - 42.68
52wk Range
34.90 - 108.47
Shares Outstanding
53,100,000
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
Top News
More News
7 Analysts Have This to Say About Arvinas
June 21, 2022
Arvinas (NASDAQ:ARVN) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 21, 2022
June 21, 2022
Upgrades
Via
Benzinga
Performance
YTD
-47.68%
-47.68%
1 Month
+2.37%
+2.37%
3 Month
-36.85%
-36.85%
6 Month
-46.31%
-46.31%
1 Year
-44.41%
-44.41%
More News
Read More
Analyst Ratings for Arvinas
May 20, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 9, 2022
May 09, 2022
Via
Benzinga
Arvinas: Q1 Earnings Insights
May 05, 2022
Via
Benzinga
What 6 Analyst Ratings Have To Say About Arvinas
April 28, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022
April 28, 2022
Via
Benzinga
Expert Ratings For Arvinas
April 06, 2022
Via
Benzinga
Arvinas: Q4 Earnings Insights
February 28, 2022
Via
Benzinga
Analyst Ratings For Arvinas
October 14, 2021
Via
Benzinga
Expert Ratings For Arvinas
September 30, 2021
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022
April 06, 2022
Via
Benzinga
Arvinas Earnings Perspective: Return On Capital Employed
March 01, 2022
Via
Benzinga
Where Arvinas Stands With Analysts
March 01, 2022
Via
Benzinga
3 Stocks To Double Down On In 2022
February 16, 2022
Via
Benzinga
Arvinas Highlights New ARV-110 Data In Prostate Cancer Patients
February 15, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2022
February 10, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2022
January 19, 2022
Via
Benzinga
5 Stocks Insiders Are Selling
December 17, 2021
Via
Benzinga
Arvinas, Pfizer's ARV-471 Shows Clinical Benefit Rate Of 40% In Pretreated Breast Cancer Patients
December 10, 2021
Via
Benzinga
The Daily Biotech Pulse: Lilly Sings Metabolic Disorder Drug Pact, Moderna Reports Positive Flu Vaccine Data, Halozyme To Buy Back Shares
December 10, 2021
Via
Benzinga
4 Stocks Insiders Are Selling
November 16, 2021
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 7, 2021
December 07, 2021
Via
Benzinga
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
December 06, 2021
Via
Benzinga
Exposures
Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021
October 14, 2021
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
